Blue

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 6, 2024
Sickle cell disease, Biotechnology, Luna Innovations, Bluebird, Blue, DSM-IV codes, Patient, Defendant, History, News, Cancer, Bank statement, False, Complaint, P.C, Elivaldogene autotemcel, File, SCD, FDA, BLA, Food

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.
  • For more information on the Luna Innovations class action go to: https://bespc.com/cases/LUNA

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, April 5, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, April 4, 2024
Sickle cell disease, Bluebird bio, AML, Telephone, Blue, Patient, History, News, LLP, CLASS, Complaint, NEXT, COST, FDA, Court, Food, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BLUE investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

bluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – BLUE

Retrieved on: 
Wednesday, April 3, 2024
Sickle cell disease, AML, Blue, Patient, History, News, Complaint, BLUE, Fraud, NEXT, FDA, Bluebird bio, Food, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).
  • Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

BLUEBIRD BIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (NASDAQ: BLUE)

Retrieved on: 
Tuesday, April 2, 2024
Sickle cell disease, Blue, District court, Patient, Food and Drug Administration, News, Cancer, Complaint, Action Replay, Food, FDA, Court, Advertising, Bluebird bio, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, April 1, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 29, 2024
Sickle cell disease, Biotechnology, Telephone, Blue, District court, DSM-IV codes, Defendant, Patient, History, News, Cancer, False, Complaint, P.C, Elivaldogene autotemcel, SCD, File, FDA, BLA, Court, Food, Person

Investors have until May 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of bluebird bio, Inc. Common Stock and Sets a Lead Plaintiff Deadline of May 28, 2024

Retrieved on: 
Thursday, March 28, 2024
Sickle cell disease, AML, Telephone, Blue, District court, Patient, History, News, LLP, E pluribus unum, BLUE, FDA, Court, Bluebird bio, Food, Person

You are hereby notified that the class action lawsuit Garry Gill v. bluebird bio, Inc., et al.

Key Points: 
  • You are hereby notified that the class action lawsuit Garry Gill v. bluebird bio, Inc., et al.
  • 1:24-cv-10803) has been commenced in the United States District Court for the District of Massachusetts.
  • Following this news, Blue’s stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.
  • If you suffered a loss in BLUE common stock, you have until May 28, 2024 to request that the Court appoint you as lead plaintiff.

China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs

Retrieved on: 
Thursday, March 28, 2024
Sclerotherapy, RMB, Conditional sentence, NDA, IND, Creativity, Small RNA, Marketing, Gastroenterology, Central nervous system, FIC, City, BIC, CMS, NRDL, Injection, Dermatology, CDMO, Commercialization, Tablet, Pharmacy, Methotrexate, Hospital, Acquisition, Gonadotropin-releasing hormone, RCT, VBP, Rheumatoid arthritis, Growth, Varicose veins, Ecosystem, Blue, Government, Ophthalmology

SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.

Key Points: 
  • SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.
  • Based on above, CMS has successfully entered into its “New Period” of innovation and internationalization development.
  • 4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs.
  • Under its compliant and efficient commercialization system, the Company's innovative products and exclusive drugs will grow steadily.

GCM Grosvenor Expands Credit Team with Two New Hires

Retrieved on: 
Thursday, March 28, 2024
RMBS, CLO, Structuring, Knowledge, Blue, Head, Risk assessment, Investment, CDO, GCM, GCMG, GCM Grosvenor, The Carlyle Group, Financial services

These strategic hires underscore GCM Grosvenor's commitment to providing world class credit investment solutions.

Key Points: 
  • These strategic hires underscore GCM Grosvenor's commitment to providing world class credit investment solutions.
  • GCM Grosvenor's credit team leverages its extensive expertise to invest across the entire credit liquidity spectrum in direct, fund, co-investment and secondary investments.
  • Before joining GCM Grosvenor, Ingles held senior positions at The Carlyle Group and PointState Capital, where he managed credit portfolios across various sectors.
  • "GCM Grosvenor is delighted to welcome Brandon Cahill and Scott Ingles to our credit team," said Fred Pollock, Chief Investment Officer of GCM Grosvenor.